4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Anavex Life Sciences Corp. (AVXL) operates in the Biotechnology industry and is headquartered in New York, United States with about 34 employees. Its market capitalization is roughly $225 million. In the fiscal year ended 2025-09-30, AVXL reported $0M in revenue and ($46M) in net income.
Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Interactive charts & full statements →
| Income statement | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($51M) | ($53M) | ($56M) | ($51M) | — |
| Net Income | ($46M) | ($43M) | ($48M) | ($48M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($7M) | ($12M) | ($14M) | ($12M) | ($14M) |
| Net Income | ($6M) | ($10M) | ($13M) | ($11M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Total Assets | $104M | $136M | $154M | $153M | — |
| Total Liabilities | $9M | $15M | $12M | $10M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVXL viewer.
About TickerBase · Data methodology & sources